More News
Want to Read Locked Articles?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Biocon Receives EU Marketing Approval for Yesafili, an Aflibercept Biosimilar
Author: Jennie Crabbe
India’s Biocon Biologics announced Sept. 20 that the European Commission had granted marketing authorization in the European Union for Yesafili, an aflibercept (Eylea) biosimilar. Yesafili is approved to treat wet age-related macular degeneration, macular edema secondary to retinal vein occlusion (branch RVO or central RVO), diabetic macular edema, and myopic choroidal neovascularization. Biocon acquired Yesafili in 2022 from Viatris, of Pittsburgh, Pennsylvania, along with biosimilars for Av...
Purchasing one of the following products will open up access to this article's content, which is also available in each comprehensive report/subscription.
This website uses cookies to ensure you get the best experience. By continuing to use our website, you consent to our use of cookies.